ADC Therapeutics SA ADCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
ADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
ADC Therapeutics Announces ZYNLONTA® Updates in Japan
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
These beaten-down stocks could bounce back in January, if history is any guide
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Trading Information
- Previous Close Price
- $1.64
- Day Range
- $1.52–1.64
- 52-Week Range
- $0.78–4.98
- Bid/Ask
- $1.56 / $1.84
- Shares Outstanding
- 127.67M
- Market Cap
- $201.71M
- Volume/Avg
- 822,997 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 193
Valuation
Metric | ADCT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.96 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ADCT |
|---|---|
Quick Ratio | 2.86 |
Current Ratio | 3.03 |
Interest Coverage | −1.03 |
Quick Ratio
ADCT
Profitability
Metric | ADCT |
|---|---|
Return on Assets (Normalized) | −24.93% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ADCT
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|?G^t#bwL | LOCK|hP$M! | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|rCBR@cn | LOCK|?y<C | $48B | |||
| Haleon PLC ADR HLN | LOCK|P<WxY>W | LOCK|jRH | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|<QYS>Y$D | LOCK|hNS | $32B | |||
| Viatris Inc VTRS | LOCK|n<Lbn%h | LOCK|sk | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|#&F | LOCK|Tl$ | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|#wq<#n | LOCK|$J | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|KGVz^!< | LOCK|V# | $6B | |||
| Perrigo Co PLC PRGO | LOCK|&?L#^Xn | LOCK|R@M | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|p!lT&Rt | LOCK|h>jQ% | $2B |
United States